Replimune stock price target raised to $27 by BMO Capital By Investing.com
On Tuesday, Replimune Group Inc . (NASDAQ:), currently trading at $11.70, saw its price target increased to $27.00 from $18.00 by BMO Capital, with the firm maintaining an Outperform rating on the stock. According to InvestingPro data, analyst targets for the stock range from $14.00 to $31.00, suggesting significant upside potential. The adjustment follows the U.S. Food and Drug Administration’s (FDA) acceptance of Replimune’s Biologics License Application (BLA) for its lead product candidate, RP1. This regulatory milestone has been positively received by investors, as it indicates progress toward the potential commercial launch of RP1.
BMO Capital’s analysis highlighted the significance of the FDA’s acceptance, noting it dispelled…
